One step small molecule approach targeting molecule PA to preserve T cell stemness and delay T cell exhaustion.
Ex vivo reprogramming overcoming the problem of CAR T cell differentiation and loss of stemness during manufacturing process.
Enable CAR T cells to increasetheir antigen-mediated cytotoxicity while limiting their exhaustion level to increase anti-tumor capacity, efficacy, and persistency in solid tumor models
Applicable to a variety of adoptive T cell therapy including CAR T, TIL and γδT cell therapy with immediate therapeutic effects and long-term protection.
